Vaxess Announces Production of The First GMP Batch of MIMIX™ Technology Vaccine Patches for an Upcoming Phase 1 Seasonal Influenza Clinical Trial; Clinical Entry Expected This Summer Based on a Successful February Pre-CTA Meeting With Health Canada.
Vaxess’s new GMP facility in Woburn has successfully produced clinical trial drug product consisting of a proprietary silk fibroin microneedle ...